Origin and characteristics of adverse events in aromatase inhibition therapy for breast cancer

Seminars in Oncology

Volumn 30, Issue 4 SUPPL. 14, 2003, Pages 58-69

  Dowsett, Mitch ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; DIGOXIN; ESTROGEN; EXEMESTANE; FORMESTANE; LETROZOLE; PHENAZONE; PHENOBARBITAL; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN CITRATE; THEOPHYLLINE DERIVATIVE; WARFARIN; ZOLEDRONIC ACID;

ARTHRALGIA; ATAXIA; BONE DISEASE; BONE PAIN; BRAIN HEMORRHAGE; BREAST CANCER; BREAST METASTASIS; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DIARRHEA; DROWSINESS; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG SAFETY; DYSPNEA; ENDOMETRIUM CANCER; FATIGUE; HEART INFARCTION; HOT FLUSH; HUMAN; LETHARGY; LIPID METABOLISM; MOOD DISORDER; NAUSEA; PRIORITY JOURNAL; PRURITUS; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; STROKE; THROMBOEMBOLISM; TREATMENT OUTCOME; UTERUS DISEASE; VAGINA BLEEDING; VAGINA DISCHARGE; VASCULAR DISEASE; VISUAL IMPAIRMENT;

EID: 0141650790     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0093-7754(03)00300-2     Document Type: Article

References (72)

1. Clemons M, Goss P: Estrogen and the risk of breast cancer. N Engl J Med 344:276-285, 2001
2. Beatson G: On the treatment of inoperable cases of carcinoma of the mamma: Suggestions for a new method of treatment with illustrative cases. Lancet 2:104-107, 1896
3. Huggins C, Dao T-Y: Adrenalectomy and oophorectomy in treatment of advanced carcinoma of the breast. JAMA 151:1388-1394, 1952
4. Harper MJ, Walpole AL: Contrasting endocrine activities of cis and trans isomers in a series of substituted triphenylethylenes. Nature 212:87, 1966
5. Harper MJ, Walpole AL: Mode of action of I.C.I. 46,474 in preventing implantation in rats. J Endocrinol 37:83-92, 1967
6. Santen RJ, Manni A, Harvey H, et al: Endocrine treatment of breast cancer in women. Endocr Rev 11:221-265, 1990
7. Rose C, Mouridsen HT: Endocrine therapy of advanced breast cancer. Acta Oncol 27:721-728, 1988
8. Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet 351:1451-1467, 1998
9. Fisher B, Costantino JP, Wickerham DL, et al: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371-1388, 1998
10. Will BP, Berthelot JM, Nobrega KM, et al: Canada's Population Health Model (POHEM): A tool for performing economic evaluations of cancer control interventions. Eur J Cancer 37:1797-1804, 2001
11. Will BP, Nobrega KM, Berthelot JM, et al: First do no harm: Extending the debate on the provision of preventive tamoxifen. Br J Cancer 85:1280-1288, 2001
12. Winer E, Hudis C, Burstein H, et al: American Society of Clinical Oncology Technology Assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: Status Report 2002. J Clin Oncol 20:3317-3327, 2002
13. Johnston SR: Endocrine manipulation in advanced breast cancer: Recent advances with SERM therapies. Clin Cancer Res 7:4376s-4387s; 4411s-4412s, 2001
14. Howell A, Robertson J, Quaresma Albano J, et al: Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 20:3396-3403, 2002
15. Osborne C, Pippen J, Jones S, et al: Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: Results of a North American trial. J Clin Oncol 20:3386-3395, 2002
16. Bonneterre J, Buzdar A, Nabholtz JM, et al: Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 92:2247-2258, 2001
17. Mouridsen H, Gershanovich M, Sun Y, et al: Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 19:2596-2606, 2001
18. Dirix LY, Piccart MJ, Lohrisch C, et al: Efficacy of and tolerance to exemestane (E) versus tamoxifen (T) in 1st line hormone therapy (HT) of postmenopausal metastatic breast cancer (MBC) patients (pts): A European Organisation for the Research and Treatment of Cancer (EORTC Breast Group) phase II trial with Pharmacia and Upjohn. Proc Am Soc Clin Oncol 20:29, 2001 (abstr 114)
19. Baird DT, Guevara A: Concentration of unconjugated estrone and estradiol in peripheral plasma in nonpregnant women throughout the menstrual cycle, castrate and postmenopausal women and in men. J Clin Endocrinol Metab 29:149-156, 1969
20. Chakravarti S, Collins WP, Forecast JD, et al: Hormonal profiles after the menopause. BMJ 2:784-787, 1976
21. Longcope C: Metabolic clearance and blood production rates of estrogens in postmenopausal women. Am J Obstet Gynecol 111:778-781, 1971
22. Brueggemeier RW: Aromatase inhibitors - Mechanisms of steroidal inhibitors. Breast Cancer Res Treat 30:31-42, 1994
23. Van den Bossche HV, Moereels H, Koymans LM: Aromatase inhibitors - Mechanisms for non-steroidal inhibitors. Breast Cancer Res Treat 30:43-55, 1994
24. Lønning PE: Aminoglutethimide enzyme induction: Pharmacological and endocrinological implications. Cancer Chemother Pharmacol 26:241-244, 1990
25. Lien EA, Anker G, Lønning PE, et al: Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide. Cancer Res 50:5851-5857, 1990
26. Dowsett M, Mehta A, King N, et al: An endocrine and pharmacokinetic study of four oral doses of formestane in postmenopausal breast cancer patients. Eur J Cancer 28:415-420, 1992
27. Dowsett M, Cunningham DC, Stein RC, et al: Dose-related endocrine effects and pharmacokinetics of oral and intramuscular 4-hydroxyandrostenedione in postmenopausal breast cancer patients. Cancer Res 49:1306-1312, 1989
28. Johannessen DC, Engan T, Di Salle E, et al: Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: A phase I study. Clin Cancer Res 3:1101-1108, 1997
29. Thurlimann B, Paridaens R, Serin D, et al: Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: A phase II multicentre multinational study. Exemestane Study Group. Eur J Cancer 33:1767-1773, 1997
30. Jones S, Vogel C, Arkhipov A, et al: Multicenter, phase II trial of exemestane as third, line hormonal therapy of postmenopausal women with metastatic breast cancer. Aromasin Study Group. J Clin Oncol 17:3418-3425, 1999
31. Kaufmann M: Steroidal side effects of exemestane. J Clin Oncol 19:2107-2108, 2001
32. Cash R, Brough A, Cohen M, et al: Aminoglutethimide (Elipten-Ciba) as an inhibitor of adrenal steroidogenesis: Mechanism of action and therapeutic trial. J Clin Endocrinol Metab 27:1239-1248, 1967
33. Harris A, Dowsett M, Smith I, et al: Endocrine effects of low dose aminoglutethimide alone in advanced postmenopausal breast cancer. Br J Cancer 47:621-627, 1983
34. Santen R, Worgul T, Lipton A, et al: Aminoglutethimide as treatment of postmenopausal women with advanced breast cancer. Ann Intern Med 96:94-101, 1982
35. Plourde PV, Dyroff M, Dowsett M, et al: ARIMIDEX: A new oral, once-a-day aromatase inhibitor. J Steroid Biochem Mol Biol 53:175-179, 1995
36. Yates RA, Dowsett M, Fisher GV, et al: Arimidex (ZD1033): A selective, potent inhibitor of aromatase in postmenopausal female volunteers. Br J Cancer 73:543-548, 1996
37. Bisagni G, Cocconi G, Scaglione F, et al: Letrozole, a new oral non-steroidal aromatase inhibitor in treating postmenopausal patients with advanced breast cancer. A pilot study. Ann Oncol 7:99-102, 1996
38. Bajetta E, Zilembo N, Dowsett M, et al: Double-blind, randomised, multicentre endocrine trial comparing two letrozole doses, in postmenopausal breast cancer patients. Eur J Cancer 35:208-213, 1999
39. Haynes B, Dowsett M, Miller W, et al: Pharmacology of letrozole. J Steroid Biochem Mol Biol 2003 (in press)
40. Evans TR, Di Salle E, Ornati G, et al: Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women. Cancer Res 52:5933-5939, 1992
41. McDonnell D, Norris J: Connections and regulation of the human estrogen receptor. Science 296:1642-1644, 2002
42. Cuzick J, Powles T, Veronesi U, et al: Overview of the main outcomes in breast-cancer prevention trials. Lancet 361:296-300, 2003
43. The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialist's Group: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359:2131-2139, 2002
44. Lokkegaard E, Pedersen AT, Heitmann BL, et al: Relation between hormone replacement therapy and ischaemic heart disease in women: Prospective observational study. BMJ 326:426-430, 2003
45. Bracamonte MP, Miller VM: Vascular effects of estrogens: Arterial protection versus venous thrombotic risk. Trends Endocrinol Metab 12:204-209, 2001
46. Elisaf MS, Bairaktari ET, Nicolaides C, et al: Effect of letrozole on the lipid profile in postmenopausal women with breast cancer. Eur J Cancer 37:1510-1513, 2001
47. Wojtacki J, Kruszewski W, Sliwinska M, et al: Effect of non-steroidal aromatase inhibitors (AI) on serum lipids profile in patients with breast cancer: Preliminary report. Eur J Cancer 36:S71, 2000 (suppl 5) (abstr 146)
48. Lohrisch C, Paridaens R, Dirix LY, et al: No adverse impact on serum lipids of the irreversible aromatase inactivator Aromasin (R) (Exemestane [E]) in first line treatment of metastatic breast cancer (MBC): Companion study to a European Organization of Research and Treatment of Cancer (Breast Group Trial with Pharmacias' Upjohn). Proc Am Soc Clin Oncol 20:43a, 2001 (abstr 167)
49. Harper-Wynne C, Ross G, Sacks N, et al: Effects of the aromatase inhibitor letrozole on normal breast epithelial cell proliferation and metabolic indices in postmenopausal women: A pilot study for breast cancer prevention. Cancer Epidemiol Biomarkers Prev 11:614-621, 2002
50. Heshmati HM, Khosla S, Robins SP, et al: Role of low levels of endogenous estrogen in regulation of bone resorption in late postmenopausal women. J Bone Miner Res 17:172-178, 2002
51. Ernst M, Schmid C, Froesch ER: Enhanced osteoblast proliferation and collagen gene expression by estradiol. Proc Natl Acad Sci U S A 85:2307-2310, 1988
52. Ireland DC, Bord S, Beavan SR, et al: Effects of estrogen on collagen synthesis by cultured human osteoblasts depend on the rate of cellular differentiation. J Cell Biochem 86:251-257, 2002
53. Turken S, Siris E, Seldin D, et al: Effects of tamoxifen on spinal bone density in women with breast cancer. J Natl Cancer Inst 81:1086-1088, 1989
54. Love RR, Mazess RB, Barden HS, et al: Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 326:852-856, 1992
55. Ward RL, Morgan G, Dalley D, et al: Tamoxifen reduces bone turnover and prevents lumbar spine and proximal femoral bone loss in early postmenopausal women. Bone Miner 22:87-94, 1993
56. Oursler MJ, Landers JP, Riggs BL, et al: Oestrogen effects on osteoblasts and osteoclasts. Ann Med 25:361-371, 1993
57. Jakob F, Siggelkow H, Homann D, et al: Local estradiol metabolism in osteoblast- and osteoclast-like cells. J Steroid Biochem Mol Biol 61:167-174, 1997
58. Mouridsen H, Gershanovich M, Sun Y, et al: Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: Analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 21:2102-2109, 2003
59. Harper-Wynne CL, Sacks NP, Shenton K, et al: Comparison of the systemic and intratumoral effects of tamoxifen and the aromatase inhibitor vorozole in postmenopausal patients with primary breast cancer. J Clin Oncol 20:1026-1035, 2002
60. Gerber B, Krause A, Muller H, et al: Effects of adjuvant tamoxifen on the endometrium in postmenopausal women with breast cancer: A prospective long-term study using transvaginal ultrasound. J Clin Oncol 18:3464-3470, 2000
61. Cheng WF, Lin HH, Torng PL, et al: Comparison of endometrial changes among symptomatic tamoxifen-treated and nontreated premenopausal and postmenopausal breast cancer patients. Gynecol Oncol 66:233-237, 1997
62. Marconi D, Exacoustos C, Cangi B, et al: Transvaginal sonographic and hysteroscopic findings in postmenopausal women receiving tamoxifen. J Am Assoc Gynecol Laparosc 4:331-339, 1997
63. Cecchini S, Ciatto S, Bonardi R, et al: Risk of endometrial cancer in breast cancer patients under long-term adjuvant treatment with tamoxifen. Tumori 84:21-23, 1998
64. Marchesoni D, Driul L, Fabiani G, et al: Endometrial histologic changes in post-menopausal breast cancer patients using tamoxifen. Int J Gynaecol Obstet 75:257-262, 2001
65. Day R, Ganz PA, Costantino JP, et al: Health-related quality of life and tamoxifen in breast cancer prevention: A report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Clin Oncol 17:2659-2669, 1999
66. Fisher B, Dignam J, Bryant J, et al: Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 88:1529-1542, 1996
67. Kruijver FP, Swaab DF: Sex hormone receptors are present in the human suprachiasmatic nucleus. Neuroendocrinology 75:296-305, 2002
68. Eiermann W, Paepke S, Appfelstaedt J, et al: Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study. Ann Oncol 12:1527-1532, 2001
69. McEwen B: Estrogen actions throughout the brain. Recent Prog Horm Res 57:357-384, 2002
70. Mortimer JE, Boucher L, Baty J, et al: Effect of tamoxifen on sexual functioning in patients with breast cancer. J Clin Oncol 17:1488-1492, 1999
71. Ganz PA, Rowland JH, Desmond K, et al: Life after breast cancer: understanding women's health-related quality of life and sexual functioning. J Clin Oncol 16:501-514, 1998
72. Ganz PA, Day R, Ware JE Jr, et al: Base-line quality-of-life assessment in the National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial. J Natl Cancer Inst 87:1372-1382, 1995